Small Molecule Therapeutics

Ibraghimov-Beskrovnaya O. 2007. Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy. Cell Cycle 6:776-779.

McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, Hutto E, Shayman JA, Grabowski GA, Aerts JM, Cheng SH, Copeland DP, Marshall J. 2007. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 91:259-267.

Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S, Hillmen P, Brettman LR, Reif S, Bonate PL. 2007. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath((R))) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol.

Sudsakorn S, Skell J, Williams DA, O'Shea TJ, Liu H. 2007. Evaluation of 3-O-methylfluorescein as a selective fluorometric substrate for CYP2C19 in human liver microsomes. Drug Metab Dispos 35:841-847.

Zhao H, Przybylska M, Wu IH, Zhang J, Siegel C, Komarnitsky S, Yew NS, Cheng SH. 2007. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56:1210-1218.

Zhao Z, Araldi GL, Xiao Y, Reddy AP, Liao Y, Karra S, Brugger N, Fischer D, Palmer E. 2007. Synthesis and evaluation of novel pyrazolidinone analogs of PGE2 as EP2 and EP4 receptors agonists. Bioorg Med Chem Lett 17:6572-6575.

Bonate PL, Arthaud L, Cantrell WR, Stephenson K, Secrist JAr, Weitman S. 2006. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 5:855-863.

Cantrell Jr. WR, Bauta WE, Engles T. 2006. Hydrogen peroxide promoted hydroxylation of haloarenes and heteroarenes. Tetrahedron Letters 47:4249-4251.

Gandhi V, Plunkett W, Bonate PL, Du M, Nowak B, Lerner S, Keating MJ. 2006. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: Strategy for treatment. Clin Cancer Res 12:4011-4017.

Ibraghimov-Beskrovnaya O, Bukanov NO. 2006. In vitro cystogenesis: The search for drugs antagonizing cyst development. Nephrol. Ther. 2:S109-114.

Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P. 2006. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 24:1917-1923.

Bourque AJ, Clark SP, Kloss A, Wang BH, Cohen AS. 2005. Characterization of quaternary ammonium oligomers by paired-ion reversed-phase liquid chromatography-mass spectrometry. Anal Chem 77:2810-2817.

Donovan JM, Plone M, Dagher R, Bree M, Marquis J. 2005. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator. Ann N Y Acad Sci 1054:492-494.

Gonzalez RR, Fong T, Belmar N, Saban M, Felsen D, Te A. 2005. Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis. J Urol 173:630-634.

Mita AC, Hammond LA, Bonate PL, Weiss G, McCreery H, Syed S, Garrison M, Chu QS, DeBono JS, Jones CB, Weitman S, Rowinsky EK. 2006. Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. Clin Cancer Res 12:5207-5215.

Modi SJ, LaCourse WR, Shansky RE. 2005. Determination of thio-based additives for biopharmaceuticals by pulsed electrochemical detection following HPLC. J Pharm Biomed Anal 37:19-25.

Donovan JM, Yardumian A, Gunawardena K, Plone M, Wonke B. 2004. The safety and pharmacokinetics of deferitrin, a novel orally available iron chelator. Blood 104:146A-147A

Lerner EN, van Zanten EH, Stewart GR. 2004. Enhanced delivery of octreotide to the brain via transnasal iontophoretic administration. J Drug Target 12:273-280.

Kane JL, Jr., Hirth BH, Liang B, Gourlie BB, Nahill S, Barsomian G. 2003. Ureas of 5-aminopyrazole and 2-aminothiazole inhibit growth of gram-positive bacteria. Bioorg Med Chem Lett 13:4463-4466.

Kuo MR, Morbidoni HR, Alland D, Sneddon SF, Gourlie BB, Staveski MM, Leonard M, Gregory JS, Janjigian AD, Yee C, Musser JM, Kreiswirth B, Iwamoto H, Perozzo R, Jacobs WR, Jr., Sacchettini JC, Fidock DA. 2003. Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data. J Biol Chem 278:20851-20859.

Liu H, Sabus C, Carter GT, Du C, Avdeef A, Tischler M. 2003. In vitro permeability of poorly aqueous soluble compounds using different solubilizers in the PAMPA assay with liquid chromatography/mass spectrometry detection. Pharm Res 20:1820-1826.

Daddi N, Suda T, D'Ovidio F, Kanaan SA, Tagawa T, Grapperhaus K, Kozower BD, Ritter JH, Yew NS, Mohanakumar T, Patterson GA. 2002. Recipient intramuscular cotransfection of naked plasmid transforming growth factor beta1 and interleukin 10 ameliorates lung graft ischemia-reperfusion injury. J Thorac Cardiovasc Surg 124:259-269.

Daddi N, Suda T, D'Ovidio F, Tagawa T, Yew NS, Mohanakumar T, Patterson GA. 2001. Recipient intramuscular gene transfer of naked plasmid TGFbeta1 ameliorates lung graft reperfusion injury. J Heart Lung Transplant 20:184.

Itano H, Zhang W, Ritter JH, McCarthy TJ, Yew NS, Mohnanakumar T, Patterson GA. 2001. Endobronchial transfection of naked viral interleukin-10 gene in rat lung allotransplantation. Ann Thorac Surg 71:1126-1133.